Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index16
i10-index24
Publications111
Citations910

Grants

12 total · 7 active

NIH #5U01CA271252-02

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$265K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~1 students

NIH #5U01CA271252-03

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$260K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~1 students

NIH #3U01CA271252-02S1

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$65K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~0 students

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

12 total · 7 active

NIH #5U01CA271252-02

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$265K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~1 students

NIH #5U01CA271252-03

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$260K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~1 students

NIH #3U01CA271252-02S1

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$65K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~0 students

NIH #1U01CA271252-01A1

Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma

Active
Amount
$358K
Period
2024-04-01 → 2029-03-31
PIs
2
Est. capacity / PI
~1 students

NIH #5U01CA284811-02

Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva

Active
Amount
$673K
Period
2023-09-08 → 2028-08-31
PIs
2
Est. capacity / PI
~2 students

NIH #1U01CA284811-01

Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva

Active
Amount
$714K
Period
2023-09-08 → 2028-08-31
PIs
2
Est. capacity / PI
~2 students

NIH #5U01CA284811-03

Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva

Active
Amount
$667K
Period
2023-09-08 → 2028-08-31
PIs
2
Est. capacity / PI
~2 students

NIH #5R01CA250069-05

Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers

Amount
$848K
Period
2020-04-01 → 2025-09-30
PIs
2
Est. capacity / PI
~0 students

NIH #3R01CA250069-04S1

Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers

Amount
$104K
Period
2020-04-01 → 2025-03-31
PIs
2
Est. capacity / PI
~0 students

NIH #5R01CA250069-03

Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers

Amount
$814K
Period
2020-04-01 → 2025-03-31
PIs
2
Est. capacity / PI
~0 students

NIH #5R01CA250069-04

Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers

Amount
$849K
Period
2020-04-01 → 2025-03-31
PIs
2
Est. capacity / PI
~0 students

NIH #3R01CA250069-03S1

Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers

Amount
$104K
Period
2020-04-01 → 2025-03-31
PIs
2
Est. capacity / PI
~0 students

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 10 of 10
Open author page on OpenAlex →